HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C∗12:02/C∗14:03  by Lin, Zhansong et al.
ArticleHIV-1 Control by NK Cells via Reduced Interaction
between KIR2DL2 and HLA-C*12:02/C*14:03Graphical AbstractHighlightsd Two HLA-KIR combinations were identified with protective
effects in HIV-1 control
d Peptide-HLA binding influences NK cell recognition of target
cells via KIR2DL2
d Peptide-HLA binding directly influences NK cell antiviral
function
d CTL-selected escape mutations influence NK cell antiviral
functionLin et al., 2016, Cell Reports 17, 2210–2220
November 22, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.10.075Authors
Zhansong Lin, Kimiko Kuroki,
Nozomi Kuse, ..., Mary Carrington,
Katsumi Maenaka, Masafumi Takiguchi
Correspondence
masafumi@kumamoto-u.ac.jp
In Brief
KIR-HLA interactions play an important
role in the antiviral functions of NK cell
during HIV-1 infection. Lin et al.
investigated HLA-KIR interplay in HIV-1
infection and found that two HLA-KIR
combinations are associated with lower
plasma viral load. Antiviral activity of
KIR2DL2+ NK cell is, therefore, fine-tuned
by peptide-HLA binding.
Cell Reports
ArticleHIV-1 Control by NK Cells
via Reduced Interaction
between KIR2DL2 and HLA-C*12:02/C*14:03
Zhansong Lin,1 Kimiko Kuroki,2 Nozomi Kuse,1 Xiaoming Sun,1 Tomohiro Akahoshi,1 Ying Qi,3 Takayuki Chikata,1
Takuya Naruto,1 Madoka Koyanagi,1 Hayato Murakoshi,1 Hiroyuki Gatanaga,1,5 Shinichi Oka,1,5 Mary Carrington,3,4
Katsumi Maenaka,2 and Masafumi Takiguchi1,6,*
1Center for AIDS Research, Kumamoto University, Chuo-ku, Kumamoto 860-0811, Japan
2Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo 060-0812, Japan
3Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Inc., Frederick National
Laboratories for Cancer Research, Frederick, MD 21701, USA
4Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139-3583, USA
5AIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo 162-8655, Japan
6Lead Contact
*Correspondence: masafumi@kumamoto-u.ac.jp
http://dx.doi.org/10.1016/j.celrep.2016.10.075SUMMARY
Natural killer (NK) cells control viral infection in part
through the interaction between killer cell immu-
noglobulin-like receptors (KIRs) and their human
leukocyte antigen (HLA) ligands. We investigated
504 anti-retroviral (ART)-free Japanese patients
chronically infected with HIV-1 and identified two
KIR/HLA combinations, KIR2DL2/HLA-C*12:02 and
KIR2DL2/HLA-C*14:03, that impact suppression of
HIV-1 replication. KIR2DL2+ NK cells suppressed
viral replication in HLA-C*14:03+ or HLA-C*12:02+
cells to a significantly greater extent than did
KIR2DL2 NK cells in vitro. Functional analysis
showed that the binding between HIV-1-derived
peptide and HLA-C*14:03 or HLA-C*12:02 influenced
KIR2DL2+ NK cell activity through reduced expres-
sion of the peptide-HLA (pHLA) complex on the cell
surface (i.e., reduced KIR2DL2 ligand expression),
rather than through reduced binding affinity of
KIR2DL2 to the respective pHLA complexes. Thus,
KIR2DL2/HLA-C*12:02 and KIR2DL2/HLA-C*14:03
compound genotypes have protective effects on
control of HIV-1 through a mechanism involving
KIR2DL2-mediated NK cell recognition of virus-
infected cells, providing additional understanding
of NK cells in HIV-1 infection.INTRODUCTION
Natural killer (NK) cells play an important role in the eradication of
target cells infected with viruses, such as hepatitis C virus (HCV)
(Khakoo et al., 2004), Ebola (Williams et al., 2015), and HIV-12210 Cell Reports 17, 2210–2220, November 22, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://(Alter et al., 2011; Barker et al., 2007). NK cell function is tuned
by the engagement of several different receptors expressed on
the cell surface, including the killer cell immunoglobulin-like
receptor (KIR) family, which consists of both inhibitory and
activating members (Kulkarni et al., 2008). The interaction
between KIR and their human leukocyte antigen (HLA) class I li-
gands on the target cells plays an important role in the regulation
of NK cell maturation (Anfossi et al., 2006; Orr and Lanier, 2010;
Yawata et al., 2008) and anti-viral functions (Altfeld and Goulder,
2007; Carrington et al., 2008; Kulkarni et al., 2008). The presence
of specific KIR-HLA combinations influences the pathogenesis
of viral infection, such as KIR3DS1 plus HLA-B Bw4-80I
(HLA-A/B alleles belonging to the Bw4 group and containing
an isoleucine at position 80), which associates with slower
progression to AIDS (Martin et al., 2002). The presence of
KIR3DL1 and its HLA-Bw4-80I ligand confers stronger killing of
HIV-1-infected cells and, consequently, better clinical outcomes
in HIV-1 infection (Alter et al., 2009; Boudreau et al., 2016; Boulet
et al., 2010; Song et al., 2014).
HLA-C has been thought to play a less important role relative
to HLA-A/-B in defense against viral infection via T cell immunity,
since it is expressed at a significantly lower level on the cell sur-
face (Apps et al., 2015). However, a recent report showed that
increasing HLA-C expression associates independently with
protection against multiple outcomes of HIV-1 infection (Apps
et al., 2013). This and several other studies (Blais et al., 2012;Ma-
kadzange et al., 2010) support an important role of HLA-C
restricted cytotoxic T lymphocytes (CTLs) in control of HIV-1.
Moreover, HLA-C alleles are the ligands for KIR2D, influencing
NK cell function after viral infection. KIR2DL3+ individuals homo-
zygous for HLA-C1 (HLA-C alleles with asparagine at position 80)
had better clinical outcomes after HCV infection (Khakoo et al.,
2004), suggesting a protective effect of this KIR2D/HLA-C com-
bination against the virus. Both the surface expression of HLA li-
gands and the peptide-HLA (pHLA)-KIR binding affinity influence
NK cell activity (Altfeld and Goulder, 2007). Unlike HLA-A anduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The Combinatorial Effect of
KIR2DL2/S2andHLA-C1Alleles onHIV-1 pVL
(A) The effect of haplotype-B-specific genes on
pVL. Haplotypes were assigned according to the
following scheme: A/A, individuals without any of
the haplotype-B-specific genes; A/B, individuals
possessing all the haplotype-A-specific genes and
at least one haplotype-B-specific gene; B/B, in-
dividuals who lack some haplotype-A-specific
genes.
(B) The effect of HLA-C1 homozygotes on pVL.
(C) The effect of HLA-C1 in combination with
KIR2DL2/S2 on pVL.
All results are given in (A)–(C) as median and in-
terquartile range. The p values were calculated by
the Mann-Whitney U test or the Kruskal-Wallis test
when comparing two ormore groups, respectively.
See also Figure S1.HLA-B alleles, the surface expression level of HLA-C alleles is
not downregulated by Nef; therefore, HLA-C may be relatively
stable after HIV-1 infection (Cohen et al., 1999; Le Gall et al.,
1998). However, a recent study demonstrated that some HIV
strains are able to down-modulate HLA-C on the infected cell
surface by Vpu (Apps et al., 2016). Thus, binding between the
pHLA-C complex and KIR2D, which is sensitive to sequence
variation of the bound peptide, might be key in regulating the ac-
tivity of NK cells (Alter et al., 2011; Fadda et al., 2012; Thananchai
et al., 2009).
KIR2DL2, a B-haplotype-specific inhibitory receptor ex-
pressed on NK cells, is capable of recognizing HIV-1-derived
peptides in the context of HLA-C molecules in virus-infected
target cells (Alter et al., 2011; Fadda et al., 2012; van Teijlingen
et al., 2014). Both in vitro and in vivo screenings discovered
that the presence of KIR2DL2 (Alter et al., 2011) or certain
KIR2DL2/HLA-C1 (van Teijlingen et al., 2014) compound geno-
types associate with specific sequence variations in the HIV-1
genome. These viral mutations confer stronger binding of
KIR2DL2 to the pHLA complex, resulting in the inhibition of
KIR2DL2+ NK cells and consequent escape of HIV-1-infected
target cells from NK-cell-mediated killing activity in vitro (Alter
et al., 2011; van Teijlingen et al., 2014). These studies suggest
that KIR2DL2+ NK cells exert immune pressure on the virus,
but direct genetic evidence to support KIR2DL2 protection in
HIV-1 infection is lacking.
All KIR studies in HIV-1 infection published to date have been
performed using Caucasian or African samples. Previous studies
in Caucasian and African cohorts reported that the presence of
some specific KIR genes and/or KIR-HLA gene combinations
confers better HIV-1 control (Alter et al., 2011; Fadda et al.,
2012; Qi et al., 2006; Song et al., 2014; van Teijlingen et al.,
2014). Japanese have different HLA and KIR frequency distribu-
tions from Caucasians or Africans (Bunce et al., 1997; Denis
et al., 2005; Hollenbach et al., 2010; Miyashita et al., 2006; Nor-
man et al., 2013), so the effects of various KIRs on viral infection
may be distinct from that in other populations. Here, we recruited
504 treatment-naive Japanese patients chronically infected with
HIV-1 and tested for correlations between the presence of each
KIR gene or KIR/HLA combination and the clinical outcome of
HIV-1 infection in this genetically distinct population. We furtherinvestigated the mechanisms for the observed genetic effects of
certain KIR/HLA combinations.
RESULTS
Effect of 2DS2/2DL2 with HLA-C*12:02 or HLA-C*14:03
on HIV-1 pVL in Chronically HIV-1-Infected Japanese
Individuals
To determine the presence of each KIR gene among our cohort
of 504 treatment-naive Japanese individuals chronically infected
with HIV-1, we first performed low-resolution analysis for KIR us-
ing multiplex PCR-SSP (sequence-specific priming) (Kulkarni
et al., 2010). Three haplotype B-specific genes, KIR2DL2,
2DS2, and 2DS3, showed significantly lower frequencies in our
cohort than that observed in the Caucasian and African cohorts
(p < 0.0001) (Figure S1). These results concur with previous
reports showing that the A haplotype is more common in the
Japanese population than haplotype B (Yawata et al., 2002).
To assess the influence of KIR on HIV-1 infection, we tested
for correlations between the presence of specific KIR haplotypes
and individual genes on plasma viral load (pVL) in our cohort. The
presence of haplotype B-specific genes had a weak beneficial
effect on the control of HIV-1 (p = 0.02884) (Figure 1A), but
none of the individual haplotype B-specific KIR genes showed
a significant effect on pVL on their own, though 2DS2 and
2DL2 genes trended toward protection (Table S1).
HLA-C alleles can be divided into two groups, HLA-C1 and
HLA-C2, based on differences at positions 77 and 80 (Winter
and Long, 1997). Previous studies showed that KIR2DL2 binds
more strongly to HLA-C1 than to HLA-C2 (Moesta et al., 2008;
Winter et al., 1998). We observed that HLA-C1 homozygotes
showed weakly lower pVL compared to all others (Figure 1B),
which could be due to HLA-C*12:02, an HLA-C1 allele known
to associate with protection in Japanese (Naruto et al., 2012).
There was no significant beneficial effect on pVL in the
KIR2DL2-HLA-C1 double-positive group as compared to all
others (Figure 1C). Since there is strong linkage disequilibrium
between KIR2DL2 and KIR2DS2 (Moesta and Parham, 2012),
we investigated these two KIR genes together and term them
as KIR2DL2/S2. We analyzed the effect of each HLA-C1 allele
with KIR2DL2/S2 in order to determine whether the weakCell Reports 17, 2210–2220, November 22, 2016 2211
Table 1. The Effect of Each C1 Allotype Allele and KIR2DL2/S2 on pVL
HLA-C Allele n
Double Positive Others
p Valuen Median pVL IQR n Median pVL IQR
01:02 139 24 4.506 3.966–4.975 479 4.544 3.959–5.000 0.928
03:03 101 19 4.623 3.973–4.982 484 4.538 3.955–5.000 0.976
03:04 112 18 4.498 3.895–5.368 485 4.544 3.961–5.000 0.974
07:02 129 21 4.643 4.041–4.965 482 4.531 3.953–5.000 0.901
08:01 62 11 4.079 3.898–5.556 492 4.544 3.970–4.998 0.836
12:02 136 26 3.872 3.398–4.540 477 4.544 4.000–5.000 <0.001
14:02 71 12 4.266 3.997–5.108 491 4.544 3.954–5.000 0.843
14:03 67 10 3.835 3.133–4.237 493 4.544 3.975–5.000 0.003
The p values were calculated by Mann-Whitney U test. IQR, interquartile range.protection observed for HLA-C1/C1 may be due to an individual
HLA-C1 allele (or alleles) in combination with its cognate recep-
tor, KIR2DL2/S2. HLA-C*12:02 and HLA-C*14:03 both showed
effects in combination with KIR2DL2/S2 on the control of
HIV-1 infection (Table 1). Individuals having KIR2DL2/S2 and
HLA-C*12:02 or HLA-C*14:03 showed significantly lower pVL
than those having one alone or neither (Figures 2A and 2B),
and, in both cases, formal tests for interactions indicated a syn-
ergistic effect between KIR2DL2/S2 with HLA-C*1202 and also
with C*14:03 (Table 2). However, KIR2DL2/S2 did not show an
effect in combination with HLA-C*14:02 (Figure 2B), even though
this allele differs from HLA-C*14:03 by only one substitution at
position 21 outside of the peptide-binding groove. Individuals
who had HLA-C*12:02 or HLA-C*14:03, but not KIR2DL2/S2,
showed significantly lower pVL (thoughweak) than double-nega-
tive individuals (Figures 2A and 2B), supporting previous work
(Naruto et al., 2012). Notably, the test for genetic interaction
where the three variables—KIR2DL2/S2, HLA-C*12:02, and
KIR2DL2/S2 plus HLA-C*12:02—were included in the model
showed that HLA-C*12:02 has a significant effect even after ac-
counting for its protective effect in the presence of KIR2DL2/S2
(Table 2). This suggests a dual mechanism of HLA-C*12:02
protection; one involving NK cell and the other involving CTL
recognition. The protection conferred byHLA-C*14:03, however,
is likely due only to its interaction with KIR2DL2/S2 (Table 2).
Finally, we analyzed the effect of other haplotype-B-specific
KIRs and their HLA ligands on the pVL, but no significant effects
were observed (Figure S2).
Stronger NK Cell Activation through Reduced
Recognition of KIR2DL2 for HIV-1-Infected
HLA-C*14:03+ Target Cells
The genetic analysis suggested that NK cells more effectively
suppress HIV-1 replication among HLA-C*14:03+KIR2DL2/S2+
HIV-1-infected individuals than in those with HLA-C*14:02+
KIR2DL2/S2+ or HLA-C*14:03+KIR2DL2/S2. Therefore, we
investigated the function of the NK cells from HLA-C*14:02+
versus HLA-C*14:03+ subjects. We established 721.221-CD4
cells transfected with HLA-C*14:02 or HLA-C*14:03 (termed
.221-C1402 and .221-C1403, respectively). .221-C1402 and
.221-C1403 cells expressed HLA-C*14 at the same level on
the cell surface (Figure S3A, left). The cell lines were then in-2212 Cell Reports 17, 2210–2220, November 22, 2016fected with HIV-1 (NL4-3 and NL4-3gagHXB2, respectively) and
co-cultured with KIR2DL2/S2+ or KIR2DL2/S2 NK cells
(CD3CD56+CD158b+) isolated from healthy donors (see Exper-
imental Procedures). KIR2DL2/S2+ NK cells suppressed HIV-1
replication in .221-C1403 at a significantly higher level than
did KIR2DL2/S2 NK cells, whereas these two NK cell subsets
suppressed HIV-1 replication at the same level in .221-C1402
cells (Figure 3A, left). In addition, 2DL2/S2+ NK cells suppressed
HIV-1 replication in .221-C1403 at a significantly higher level
than that in .221-C1402, whereas 2DL2/S2 NK cells sup-
pressed HIV-1 replication in these two target cell lines at the
same level (Figure 3A, right). The NK cell reaction assay showed
that KIR2DL2/S2+ NK cells produced significantly higher levels
of reaction markers (interferon-g [IFN-g] and CD107a) after stim-
ulation with HIV-1-infected .221-C1403 cells than they did
after stimulation with .221-C1402 cells, whereas 2DL2/S2
NK cells produced similar levels of reaction markers after stimu-
lation with .221-C1403 or .221-C1402 cells infected with HIV-1
(Figure 3B). These results indicate that KIR2DL2/S2+ NK cells
are more strongly reacted and suppressive of viral replication
in the presence of HLA-C*14:03 ligand relative to other KIR/
HLA combinations. Further confirmation of these results was
generated using primary CD4+ T cells from HLA-C*14:02 or
HLA-C*14:03 homozygous donors (Figure 3C).
We next tested the ability of NK cells to recognize cells
expressing HLA-C*14:02 or HLA-C*14:03 pulsed with an
HLA-C*14-restricted, HIV-1-derived, CTL epitope peptide,
Gag-LL8 (Horton et al., 2006). HLA-C*14:02 or HLA-C*14:03
was transfected into the RMA-S cell line (RMA-S-C1402 and
RMA-S-C1403, respectively). RMA-S-C1402 and RMA-S-
C1403 cells expressed similar levels of HLA-C*14 on the cell
surface at 26C or at 37C (Figure S3A, right). The cells were
pulsed with Gag-LL8 and used as targets. Bulk NK cells from
KIR2DL2/S2+ donors stimulated with Gag-LL8-pulsed RMA-S-
C1403 showed a significantly higher reaction level than those
stimulated with Gag-LL8-pulsed RMA-S-C1402 (Figure 3D), in
concert with results using HIV-1-infected .221 targets
(Figures 3A–3C). This difference in reaction level may be due to
distinct binding affinities of Gag-LL8 for HLA-C*14:02 versus
HLA-C*14:03 molecules, which, in turn, may result in differential
levels of stability of the HLA molecules, thereby affecting
KIR recognition. Indeed, HLA-C*14:02 molecules showed a
Figure 2. Effect of KIR2DL2/S2 and HLA-C*12:02 or HLA-C*14:03 on HIV-1 pVL
(A) The effect of HLA-C*12:02 and KIR2DL2/S2 on pVL.
(B) The effect of HLA-C*14:03 or HLA-C*14:02 and KIR2DL2/S2 on pVL.
All results are given in (A) and (B) as median and interquartile range. The p values were calculated by the Mann-Whitney U test or the Kruskal-Wallis test when
comparing two or more groups, respectively. N.S., not significant.
See also Figures S1 and S2 and Table S1.significantly greater expression index in the presence ofGag-LL8
thandidHLA-C*14:03molecules (Figure 3E). Thegreater reaction
and viral suppression conferred by C*14:03 in the presence of
KIR2DL2/S2, yet higher expression index of Gag-LL8/HLA-
C*14:02 complexes, would suggest that the mechanism distin-
guishing the effects of HLA-C*14:02 versus HLA-C*14:03 in-
volves inhibition by KIR2DL2 rather than activation by KIR2DS2.
We tested whether the binding affinity of KIR for its ligand af-
fects NK cell function using surface plasmon resonance (SPR)
analysis. KIR2DS2 exhibited little binding to these HLA mole-
cules (Figure 3F), indicating that the mechanism of differential
viral control across HLA genotypes does not involve KIR2DS2.
Further, the binding affinity of KIR2DL2 for Gag-LL8-HLA-
C*14:02was similar to that forGag-LL8-HLA-C*14:03 (Figure 3F),
excluding the possibility that different affinities of KIR2DL2 for
these two HLA-C*14 molecules results in the observed differen-
tial levels of HIV control. Taken together, the results raise the
possibility that lower expression of Gag-LL8-HLA-C*14:03 on
the cell surface of HIV-1-infected HLA-C*14:03+ target cells
may reduce the level of KIR2DL2-mediated NK cell inhibition
relative to that involving HLA-C*14:02 target cells.
In order to determinewhether these resultswere specific to the
Gag-LL8 epitope, we measured the expression index of four
additional HLA-C*14-restricted, HIV-1-derived peptides and
showed that all four peptides bind to HLA-C*14:02 with signifi-
cantly higher affinity than they do toHLA-C*14:03molecules (Fig-
ure S3B). Thus, differential expression levels of HLA-C*14:02
versus HLA-C*14:03 in the context of HIV-1-bound peptides
likely affect KIR2DL2 recognition and outcome toHIV-1 infection.
Effective Function of KIR2DL2/S2+NK Cells for
HLA-C*12:02+ Target Cells Infected with HIV-1
We tested whether NK cells from KIR2DL2/S2+ subjects were
capable of suppressing HIV-1-infected HLA-C*12:02+ cells to agreater extent than NK cells from KIR2DL2/S2 subjects.
No difference was observed, however, between NK cells sorted
from KIR2DL2/S2+ versus those from KIR2DL2/S2 donors in
their ability to suppress the replication of NL4-3 (Figure 4A,
left), suggesting that the effect of KIR2DL2/S2 with HLA-
C*12:02 is due to a different mechanism than that involving the
two subtypes of HLA-C*14. Previous studies suggested that
sequence variations within HLA-binding peptides may influence
NK cell activity (Fadda et al., 2012). We previously demonstrated
that a Val-to-Ala substitution at Pol 464, which is located at the
ninth position of the HLA-C*12:02-restricted epitope Pol-IY10,
significantly impairs the killing activity of Pol-IY10-specific
CTLs (Honda et al., 2011). In order to determine whether this mu-
tation has an effect on the suppression of viral proliferation by
KIR2DL2/S2+ NK cells, we performed viral suppression assays
on both wild-type (WT) and 9A mutant viruses. KIR2DL2/
S2+NK cells suppressed the replication of the 9A virus in
HIV-1-infected .221-C*1202 cells more effectively than
KIR2DL2/S2 NK cells did (Figure 4A, right), whereas both NK
cells suppressed the replication ofWT viruses to the same extent
(Figure 4A, left). In addition, 2DL2/S2+ NK cells suppressed the
replication of the 9A virus at a significantly higher level than
that of WT virus, whereas 2DL2/S2 NK cells suppressed that
of both viruses at the same level (Figure 4A, right). The NK cell re-
action assay showed that KIR2DL2/S2+ NK cells produced
significantly higher levels of reaction markers after stimulation
with the 9A-virus-infected .221-C1202 cells than they did after
stimulation with the WT-virus-infected .221-C1202 cells,
whereas 2DL2/S2 NK cells produced similar levels of reaction
markers after stimulation with both cells (Figure 4B). The ability
of KIR2DL2/S2+ NK cells to suppress viral replication more
robustly than KIR2DL2/S2 NK cells was confirmed in the
experiments using primary CD4+ T cells infected in vitro from
HLA-C*12:02 homozygous donors (Figure 4C).Cell Reports 17, 2210–2220, November 22, 2016 2213
Table 2. The Synergistic Effects of KIR/HLA Combinations on
pVL
Three Variables
in Each Model n Mean logVL SE p Value
KIR2DL2/S2 85 4.21 0.09 0.82
Others 418 4.24 0.10
HLA-C*12:02 136 4.11 0.09 0.02
Others 367 4.33 0.10
Double positive 26 3.99 0.18 0.03
Others 477 4.45 0.06
KIR2DL2/S2 85 4.02 0.14 0.31
Others 418 4.13 0.14
HLA-C*14:03 67 3.98 0.14 0.10
Others 436 4.17 0.14
Double positive 10 3.76 0.27 0.03
Others 493 4.40 0.07
The p values were generated by logistical regression model with an inter-
action term.NK cell functional assays revealed that RMA-S-C1202 cells
pre-pulsed with the mutant peptide stimulated KIR2DL2/S2+
NK cells at significantly higher levels than did those pre-pulsed
with the WT peptide (Figure 4D), suggesting that the 9Amutation
influenced the recognition of the target cells by NK cells via
KIR2DL2/S2. To clarify how the 9A mutation influences
KIR2DL2/S2+ NK cell reactivity, we measured the expression in-
dex of the 9A and WT peptides to HLA-C*12:02 molecules. The
results showed that the 9A mutant peptide had a significantly
weaker expression index (Figure 4E), raising the possibility that
the 9A mutation reduced the expression level of HLA-C*12:02
molecules on cells infected with the 9A mutant virus. We further
tested for direct binding of KIR2DL2 and KIR2DS2 to
HLA-C*12:02-peptide complexes by using SPR. The binding
affinity of KIR2DL2 to WT Pol-IY10-HLA-C*12:02 was the same
as that observed for the mutant Pol-IY10-HLA-C*12:02 com-
plexes, whereas KIR2DS2 did not bind to these HLA molecules
(Figure 4F).
These results support a model in which NK cells expressing
KIR2DL2 are more readily reacted in response to the HLA-
C*12:02-associated escape mutation in the Pol-IY10 epitope
than they are to the WT form of this epitope due to lower expres-
sion of HLA-C*12:02 when complexed with the mutant peptide.
Thus, the protective effects of both HLA-C*14:03 and -C*12:02
appear to be mediated by the lower expression of these
allotypes in the presence of corresponding HIV peptides and
diminished KIR2DL2 recognition, resulting in greater NK cell
activation.
DISCUSSION
In the present study, we first performed genetic analyses using
the same cohort of 504 treatment-naive Japanese individuals
chronically infected with HIV-1 in which the effect of HLA alleles
on clinical outcome was previously analyzed (Naruto et al.,
2012). We identified two KIR/HLA combinations, KIR2DL2/S2/2214 Cell Reports 17, 2210–2220, November 22, 2016HLA-C*12:02 and KIR2DL2/S2/HLA-C*14:03, that significantly
correlated with lower pVL in the Japanese population, in which
HLA-C*12:02 and C*14:03 were detected at a frequency of
22.3% and 13.3%, respectively (Ikeda et al., 2015). Previous
studies showed the combined effect of KIR2DL2 and two
HLA-C alleles, HLA-C*01:02 (Alter et al., 2011; Fadda et al.,
2012) and C*03:04 (van Teijlingen et al., 2014), on NK cell func-
tion and HIV-1 infection in Caucasian cohorts, which have
extremely low frequencies of HLA-C*12:02 and C*14:03.
The results of viral suppression and NK cell reaction assays
demonstrated that the presence of KIR2DL2/S2 combined with
HLA-C*14:03 confers stronger inhibition of HIV-1 replication
and a higher level of IFN-g secretion and degranulation than
does the presence of either one alone. Interestingly, HLA-
C*14:02 did not show such an effect with KIR2DL2/S2 in the
genetic analysis, nor did it in the viral suppression or NK cell re-
action assays. HLA-C*14:02 and -C*14:03 differ by only a single
substitution at position 21 located outside of the peptide-binding
cleft. NK cell reaction assays using RMA-S-C1402 or RMA-
S-C1403 pre-pulsed with the Gag-LL8 epitope peptide demon-
strated that KIR2DL2/S2+ NK cells stimulated with the peptide-
pulsed RMA-S-C1403 cells were reacted at a significantly higher
level than those stimulated with peptide-pulsed RMA-S-C1402
cells. This result suggested the possibility of lower expression
of HLA-C*14:03 on cells relative to HLA-C*14:02, perhaps due
to lower peptide affinity for HLA-C*14:03 relative to that for
HLA-C*14:02. Indeed, HLA stabilization assay showed that five
HIV-1 peptides had higher binding affinity to HLA-C*14:02 than
to HLA-C*14:03. Thus, the single-amino-acid difference be-
tween HLA-C*14:02 and HLA-C*14:03 outside of the binding
cleft influences the binding affinity of the peptide bound to these
HLA molecules and, consequently, modulates the recognition of
HIV-1-infected target cells by NK cells through KIR2DL2.
Several studies have reported that peptide sequence varia-
tions may enhance the binding of inhibitory KIRs to the pHLA
complexes and, consequently, downregulate the activity of NK
cells (Alter et al., 2011; Fadda et al., 2012; Ho¨lzemer et al.,
2015; Thananchai et al., 2009; van Teijlingen et al., 2014). How-
ever, we showed that the 9A mutation in Pol-IY10 did not
influence the direct binding of KIR2DL2 to the pHLA-C*12:02
complex, even though this mutation resulted in greater
KIR2LD2+ NK cell activation and resulted in stronger inhibition
of replication of the virus carrying this mutation. Rather, the
HLA stabilization assay showed that the 9A mutation reduced
pHLA-binding affinity. Taken together, our data suggest that
peptide sequence variation influences the pHLA-binding affinity,
thereby altering the expression level of pHLA on the cell surface,
which consequently regulates the recognition by and activation
of NK cells without changing the KIR-pHLA-binding affinity. We
analyzed the association between this mutation and HLA-
C*12:02 in 363 chronically HIV-1-infected individuals and
showed that thismutation is detected at a significantly higher fre-
quency in HLA-C*12:02+ individuals than in those missing this
allele (Figure S4A), confirming a previous smaller cohort study
(Honda et al., 2011). There is no significant difference in the
frequency of the 9A escape mutation between KIR2DL2/S2+
and KIR2DL2/S2 HLA-C*12:02+ individuals (Figure S4B),
excluding the selection of this mutation by NK cells.
Figure 3. Inhibition of Viral Replication in HLA-C*14:02- or 14:03-Positive Target Cells by NK Cells
(A) Percentage of viral suppression in .221-C1402 or .221-C1403 cell lines infected with NL4-3gagHXB2 by bulk NK cells sorted from three KIR2DL2/S2+ or three
2DL2/S2 individuals. Viral suppression ability of NK cells was tested in triplicate samples from each individual. The left panel shows the comparison of the viral
suppression level between KIR2DL2/S2+ and 2DL2/S2 NK cells; the right panel compares the viral suppression level for each individual depending on HLA
genotype. Viral suppression ability of KIR2DL2/S2+ and 2DL2/S2 NK cells for .221 cells infected with NL4-3gagHXB2 was 89.6% ± 4.2% and 87.1% ± 8.0%,
respectively.
(B) Comparison of NK cell reactivity upon stimulation with NL4-3gagHXB2-infected .221-C1402 and .221-C1403 cells for each individual. Relative NK cell reactivity
was calculated by determining the frequency of IFN-g+ and/or CD107a+ NK cells as described in the Experimental Procedures.
(C) Percentage of viral suppression using NL4-3gagHXB2-virus-infected CD4 T cells separated from HLA-C*14:02 or -C*14:03 homozygous patients by bulk NK
cells sorted from three KIR2DL2/S2+ or three 2DL2/S2 individuals. Viral suppression ability of NK cells was tested in triplicate from each individual. The left panel
shows the comparison of the viral suppression level between KIR2DL2/S2+ and 2DL2/S2NK cells; the right panel compares the viral suppression levels for each
individual.
(D) Reactivity of bulk NK cells sorted fromKIR2DL2/S2+ individuals after stimulation with RMA-S-C1402 or -C1403 cell lines pulsed with epitope peptide Gag-LL8
(30 mM).
(E) Expression of HLA molecules on RMA-S-C1402 or -C1403 cell lines pulsed with epitope peptides Gag-LL8.
(F) Binding affinity of HLA-C*14:02 or C*14:03 monomers folded with Gag-LL8 to KIR2DL2 or KIR2DS2molecules wasmeasured by surface plasmon resonance.
The KD values were determined using equilibrium-binding curves and Scatchard analysis of equilibrium binding. RU, relative units.
In (A)–(E), p values (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) were calculated by theMann-Whitney U test; results are given asmeanwith SD. All of the data
were acquired by triplicated experiments. N.S., not significant.
See also Figure S3.
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Figure 4. Inhibition of Viral Replication in HLA-C*12:02-Positive Target Cells by NK Cells
(A) Percentage of viral suppression in NL4-3 (WT)- or NL4-3pol 464-10-9A (9A)-virus-infected .221-C1202 cells by bulk NK cells sorted from three KIR2DL2/S2
+ or
three 2DL2/S2 individuals. Viral suppression ability of NK cells was tested in triplicate from each individual. The left panel shows the comparison of the viral
suppression level between the KIR2DL2/S2+ versus 2DL2/S2NK cells; the right panel compares the viral suppression level between target cells infectedwithWT
and 9A viruses for each individual.
(B) The comparison of NK cell reactivity upon stimulation with WT- and 9A-mutant-virus-infected .221-C1202 cells for each individual. Relative NK cell reactivity
was calculated by determining the frequency of IFN-g+ and/or CD107a+ NK cells as described in the Experimental Procedures.
(C) Percentage of viral suppression in WT- or 9A-mutant-virus-infected CD4 T cells isolated from an HLA-C*12:02 homozygous healthy donor by bulk NK cells
sorted from three KIR2DL2/S2+ or three 2DL2/S2 individuals. Viral suppression ability of NK cells was tested in triplicate from each individual. The left panel
shows the comparison of the viral suppression level between KIR2DL2/S2+ and 2DL2/S2NK cells; the right panel compares the viral suppression level between
target cells infected with WT and 9A viruses for each individual.
(D) Reactivity of bulk NK cells sorted from KIR2DL2/S2+ individuals after stimulation with RMA-S-C1202 cell lines pulsed with Pol-IY10 (WT) or 9Amutant peptide
(100 mM).
(E) Expression level of HLA molecules on RMA-S-C1202 cell lines pulsed with the Pol-IY10 (WT) or 9A mutant peptides.
(F) Binding affinity of HLA-C*12:02 monomers folded with WT or mutant Pol-IY10 to KIR2DL2 or KIR2DS2 molecules was measured by surface plasmon
resonance. WT-1 and WT-2 represent the duplicated experiments for the WT peptide-HLA complexes; 9A-1 and 9A-2 represent the duplicated experiments for
(legend continued on next page)
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HIV-1 sequence variations have been reported to be selected
by NK-cell-mediated immune pressure (Alter et al., 2011; van
Teijlingen et al., 2014). These KIR-associated sequence varia-
tions impair NK cell function by facilitating the binding and recog-
nition of specific HLA alleles to related inhibitory KIRs. On the
other hand, it is widely known that strong immune pressure
conferred by HIV-1-specific CTLs selects escape mutations
within HIV-1 epitopes. These mutations accumulate not only in
individuals possessing related HLA alleles but also in popula-
tions, to some extent (Chikata et al., 2014; Kawashima et al.,
2009; Moore et al., 2002). The impact of these CTL-selected
escape mutations on KIR recognition and NK cell function is
now beginning to be considered. A previous study reported
that a single-amino-acid variant within an HLA-Cw4-restricted
epitope impaired both CTL recognition and NK cell function by
increasing the direct binding of the pHLA complex to KIR2DL1
molecules, implying that a CTL escape mutation can also affect
NK cell recognition (Thananchai et al., 2009).We showed that the
9A escape mutation selected by the HLA-C*12:02-restricted
CTLs, which accumulates in HLA-C*12:02+ individuals without
reversion (Honda et al., 2011), activates KIR2DL2+ NK cells,
leading to suppressed replication of the mutant virus replication.
The 9A mutation was detected in approximately 40% of
KIR2DL2+HLA-C*12:02+ Japanese individuals (Figure S4A).
These findings suggest that the 9A mutation enhances the
recognition of 2DL2+ NK cells and contributes to the protective
effect of the KIR2DL2/HLA-C*12:02 compound genotype on
HIV-1 control at the population level.
We describe herein a comprehensive study on the synergistic
effect of KIR-HLA combinations in the Japanese population and
identified two new combinations, KIR2LD2/HLA-C*12:02 and
KIR2LD2/HLA-C*14:03, that have protective effects on HIV-1
control. Furthermore, the mechanism involves NK cell reaction
via decreased KIR2DL2 recognition of HIV-1-infected cells.
The impact of a CTL escape mutation on KIR recognition and
NK cell reaction that we describe herein underscores the deli-
cate network between the acquired and innate immune systems
upon HIV-1 infection.
EXPERIMENTAL PROCEDURES
Ethics Statement
The study was approved by the Ethics Committees of Kumamoto
University (RINRI-540 and GENOME-210) and the National Center for
Global Health and Medicine (NCGM-A-000172-00). The written informed
consent was obtained from all individuals according to the Declaration of
Helsinki.
Study Subjects
504 treatment naive HIV-1 chronically infected individuals and 6 HIV-1 sero-
negative individuals were recruited. Their plasma and peripheral blood mono-
nuclear cells (PBMCs) were separated from whole blood. HLA genotypes of
the HLA-A, -B, and -C alleles were identified by the Luminex microbead
method at the NPO HLA Laboratory.the mutant (the V9A mutation in Pol-IY10 epitope) peptide-HLA complex. The
analysis of equilibrium binding. RU, relative units.
In (A)–(E), p values (**p < 0.01; ***p < 0.001; ****p < 0.0001) were calculated by the
acquired by triplicate experiments.
See also Figure S4.KIR Typing
The low-resolution KIR typing, which is aimed to detect the presence or
absence of 16 KIR genes, was performed by using multiplex PCR-SSP (Kul-
karni et al., 2010). Based on the two haplotypes, individuals were classified
as follows: A/A, individuals without any of the haplotype B-specific genes
(or, we can say, individuals having only 3DL3, 2DL3, 2DP1, 2DL1, 2DL1,
3DP1, 2DL4, 3DL1, 2DS4, and 3DL2); A/B, individuals possessing all the
haplotype A-specific genes (2DL3, 3DL1, and 2DS4) and at least one haplo-
type B-specific gene (2DS2, 2DL2, 2DL5, 2DS5, 3DS1, 2DS3, and 2DS1);
B/B, individuals who lack some of the haplotype A-specific genes (especially
2DS4).
NK Cell Sorting and Culture
Cryopreserved PBMC samples from four healthy donors (all had KIR2DL3,
whereas three had KIR2DL2/S2 but one did not) were thawed, divided, and
immediately stained with anti-CD3 monoclonal antibody (mAb), anti-CD16
mAb, anti-CD56 mAb, GL183 anti-CD158b mAb (BD Pharmingen), and
7AAD (BD Pharmingen). CD158b is the cell surface marker for KIR2DL2,
KIR2DS2, and KIR2DL3, which share a similar extracellular structure. One
thousand CD3CD16+CD56+CD158b+7AAD cells were sorted into a
96-well plate by using a FACSAria I cell sorter (BD Biosciences). Sorted NK
cells from 2DL2/S2+ or 2DL2/S2 donors were stained with anti-KIR2DL3
mAbs (R&D Systems), and the frequency of KIR2DL3+ cells was measured
by flow cytometry. NK cells from 2DL2/S2+ donors contained only 4.1%–
5.9% KIR2DL3+ cells, whereas all of the NK cells from 2DL2/S2 donors ex-
pressed KIR2DL3. Sorted cells were cultured in CellGro SCGM serum-free
medium (CellGenix) supplemented with 10% fetal bovine serum (FBS) and
400 U/mL recombinant interleukin-2 (rIL-2) for 1–2 months. These cultured
NK cells were tested for the expression of CD158b, and all of them expressed
CD158b. The reactivity of the cultured NK cells was tested against that of K562
cells by measuring the frequency of NK cells producing IFN-g or expressing
CD107a. They were 99.3%–100%.
Target Cells
721.221-C1202-CD4 cells were generated in our lab as previously described
(Honda et al., 2011). 721.221-C1402 and -C1403 cell lines were generated
by the transfection of HLA-C*14:02 and -C*14:03 genes into 721.221-CD4
cell lines, respectively. These cells express the same level of HLA-C14 on
the cell surface. RMA-S-C1202 cells were generated in our lab as previously
described (Kuse et al., 2015). RMA-S-C1402 and -C1403 cell lines were gener-
ated by the transfection of HLA-C*14:02 and -C*14:03 genes into RMA-S cell
lines, respectively. The RMA-S cell line is a TAP2-defected cell line derived
from mice. They express high levels of empty MHC molecules (i.e., without
binding peptide) on the cell surface when cultured at 26C and extremely
low levels when cultured at 37C (Ljunggren et al., 1990). CD4+ T cells were
separated from donors homozygous for HLA-C*12:02, -C*14:02, or -C*14:03
by using magnetic-activated cell sorting (MACS) separation columns (Miltenyi
Biotec).
HIV-1 Clones
The proviral clones NL4-3 (Akari et al., 2000) and the chimeric virus clone
NL4-3gagHXB2 (Fujiwara et al., 2005) were previously described. These two
clones were used asWT virus controls. The NL4-3pol 464-10-9A (9Amutant virus)
was generated by introducing the Pol463-10-9A mutation into NL-432 using
site-directed mutagenesis (Invitrogen) as previously described (Honda et al.,
2011).
Viral Suppression Assay
Target cells (CD4 T cells or 721.221 cell lines) were incubated with a given
HIV-1 clone for 6 hr at 37C after a 30-min centrifugation with 1,000 rpm atKD values were determined using equilibrium-binding curves and Scatchard
Mann-Whitney U test; results are given as mean with SD. All of the data were
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4C. After a wash three times by R10, the infected cells were co-cultured with
different sorted NK cell lines (effector: target [E:T] ratio = 0.1:1). From day 4 to
day 7 post-infection, 30 mL supernatant was collected and stored at 30C;
and the concentration of p24 antigen (p24 Ag) was measured by p24
ELISA, using the HIV Type 1 p24 Antigen ELISA kit (ZeptoMEtrix). The percent-
age of suppression of HIV-1 replication was calculated as follows:
percent suppression = (1  [concentration of p24 Ag in the supernatant
of HIV-1-infected target cells co-cultured with an NK cell line/concen-
tration of p24 Ag in the supernatant of HIV-1-infected target cells without
effectors]) 3 100.
NK Cell Stimulation and Reaction Assay
For HIV-1-infected target cells, 721.221 cell lines were infected with specific
HIV-1 strains for 3 days; viral infectivity was measured by intracellular p24
staining. Target cells with a similar frequency of p24-positive populations
were selected and co-cultured with a specific NK cell line (E:T ratio = 0.1:1)
for 1 day. For peptide-pulsed RMA-S cells, RMA-S cell lines were pre-cultured
at 26C for 18 hr and then incubated with different concentrations of a specific
synthesized peptide at same temperature for 1 hr; cells were then co-cultured
with a specific NK cell line (E:T ratio = 0.1:1) for 1 hr at 37C; brefeldin A
(6 mg/mL) and Alexa Fluor 647-labeled anti-mouse CD107a (LAMP-1) mAb
(BioLegend) were added, and cells were cultured for another 5 hr; NK cells
were then stained with PE (phycoerythrin)-labeled anti-CD56 mAb (BD
Pharmingen), FITC (fluorescein isothiocyanate)-labeled anti-CD158b mAb
(BD Pharmingen), and 7AAD (BD Pharmingen) and were analyzed by FACS
(fluorescence-activated cell sorting) using the BD FACSCanto II.
CD107a/IFN-g double-positive and single-positive 7AADCD56+CD158b+
cells were all counted as reacted NK cell populations. For HIV-1-infected
target cells, relative NK cell reactivity (%) was calculated as follows: % reacted
NK cells co-cultured with HIV-1-infected target cell lines% reacted NK cells
co-cultured with uninfected target cell lines. For peptide-pulsed RMA-S cells,
NK cell reactivity index was calculated as follows: (% reacted NK cells co-
cultured with peptide-pulsed RMA-S cell lines  % reacted NK cells without
target cells)/(% reacted NK cells co-cultured RMA-S cell lines without peptide
pulsing % reacted NK cells without target cells).
Peptide-HLA Stabilization Assay
The binding of peptides to HLA class I molecules was measured as previously
described (Takamiya et al., 1994). Briefly, RMA-S cell lines were pre-cultured
at 26C for 18 hr to fully express and present empty HLA class I molecules on
the cell surface and then incubated with different concentrations of peptide at
same temperature for 1 hr; cells were then incubated at 37C for another 3 hr.
After incubation, cells were stained with anti-HLA class I a3 domain mAb
TP25.99 (Tanabe et al., 1992) and, subsequently, with FITC-conjugated sheep
immunoglobulin G (IgG) (Jackson ImmunoResearch Laboratories). The sur-
face expression of these HLA-C molecules was measured by flow cytometry
(BD FACSCanto II). The HLA expression index was calculated as follows:
(MFI [mean fluorescence intensity] of RMA-S cells pre-pulsed with peptide 
MFI of RMA-S cells without peptide pulsing)/(MFI of RMA-S cells kept at
26C indefinitely  MFI of RMA-S cells without peptide pulsing). RMA-S cell
lines expressing HLA-C*14:02 or HLA-C*14:03 cultured at 26C present the
same level of HLA-C14 on the cell surface.
Peptide-HLA Complex and KIR Binding Assay
HLA-C*12:02, HLA-C*14:02, and HLA-C*14:03 monomers were made as
previously described (Fan et al., 2001). HLA-C*12:02 monomers were folded
with the following peptides: ILKEPVHGVY (WT Pol-IY10) and ILKEPVHGAY
(9A Pol-IY10), respectively. HLA-C*14:02 and C*14:03 monomers were folded
with the peptide LYNTVATL (Gag-LL8). Surface plasmon resonance studies
were performed by using a BIAcore3000 (GE Healthcare) as previously
described (Dong et al., 2004; Thananchai et al., 2009). Experiments were per-
formed at 25C.HBS-EPbuffer (GEHealthcare) was used as the runningbuffer.
KD (dissociation constant) values and kinetics were measured either by
Scatchard plots or by curve fitting of the data to the Langmuir binding
isotherm. All analyses were performed by using BIAevaluation software
(version 4.1.1; GEHealthcare), and graphs weremade by usingOrigin software
(version 7; Microcal Software).2218 Cell Reports 17, 2210–2220, November 22, 2016Statistical Analysis
We performed statistical analyses by using Prism (GraphPad software) and
Origin software. For the comparison between two groups, we used the
Mann-Whitney U test. For the comparison between more than three groups,
we used the Kruskal-Wallis test. We performed a logistical regression model
with an interaction term to analyze the synergistic effect of KIR/HLA combina-
tions on pVL.
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